LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.14 · Revenue $48.77M · 2 analysts
Est. EPS $-0.00 · Revenue $61.38M · 2 analysts
Est. EPS $-0.52 · Revenue $207.54M · 3 analysts
Est. EPS $-0.04 · Revenue $57.53M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $194.1M | -8.7% | -5.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-7.1M | +62.4% | +20.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +79.8% | -10.1% | +4.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -4.0% | +48.0% | +15.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -3.7% | +58.8% | +15.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-1.2M | -120.7% | -3196.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -0.6% | -122.7% | -3385.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 27.3% | +106.0% | +84.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.25x | +54.2% | -13.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $70.4M | -2.8% | -14.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.23 vs -0.21 | -8.1% | -0.16 vs -0.14 | -14.6% |
| Revenue Surprise | $194.1M vs $234.0M | -17.1% | $47.3M vs $48.8M | -3.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | LAROVERE JOAN | director | Common Stock | A | 35,000 | — |
| Aug 11, 2026 | Strawn John R Jr | director | Common Stock | A | 35,000 | — |
| Aug 11, 2026 | DiTrolio Joseph | director | Common Stock | A | 35,000 | — |
| Aug 11, 2026 | Simon Roberto | director | Common Stock | A | 35,000 | — |
| Aug 11, 2026 | MACRAE CALUM ARCHIBALD | director | Common Stock | A | 35,000 | — |
Operator: Good afternoon, and thank you for joining us today to discuss LifeMD's results for the second quarter ending June 30, 2026. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer, and Atul Kavthekar, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question and answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and in other filings LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on information available to the company as of today, August 5, 2026. The company assumes no obligation to update or revise any forward-looking statements after today's call, except as required by law. Management will also discuss certain non-GAAP financial measures that the company believes are useful in evaluating its performance. Reconciliation to the most comparable GAAP measures can be found in the press release issued earlier today. Today's call is being recorded and will be available for replay in the Investor Relations section of the company's website. Now I would like to turn the call over to LifeMD's Chairman and Chief Executive Officer, Justin Schreiber. Justin? Justin Schreiber: Thank you, Operator, and good afternoon, everyone. After the market closed today, we issued our second quarter earnings release and filed our Form 10-Q. We've also posted an updated investor presentation on our Investor Relations website. I encourage everyone to review those materials. I want to begin by addressing the quarter directly. Revenue was $47.3 million within the guidance range we provided. Adjusted EBITDA was a loss of approximately $3.5 million, reflecting elevated customer acquisition costs earlier in the quarter and a new $39 introductory offer. While elevated media costs were transient and adjusted EBITDA improved throughout the quarter, we missed our own target, and I want to be direct about why. This quarter, we restructured our customer acquisition model. We transformed our leadership team. We advanced our transition toward branded GLP-1 therapies and longer duration members. We launched an important pharmaceutical collaboration with Halozyme. We continue to scale our pharmacy, women's health, insurance, Medicare, enterprise, and technology capabilities, and we took tangible steps to reduce our reliance on paid media as the principal engine of growth. We knew these changes would carry near-term cost. What we underestimated was the near-term pressure of those changes on profitability. And that's a miss we own. I have said before that our model is simple, quality care, quality products, and quality revenue. Our objective is not …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Justin Schreiber | Chairman & Chief Executive Officer | USD 777,075 | Male | 1983 | Active |
Atul Kavthekar | Chief Financial Officer | USD 608,728 | Male | — | Active |
Umesh Sripad | Chief Technology Officer | USD 540,873 | Male | — | Active |
Stefan Galluppi | Chief Innovation Officer | USD 444,575 | Male | 1987 | Active |
Shane Biffar | Chief Compliance Officer & Deputy General Counsel | USD 411,558 | Male | 1983 | Active |
Shayna Webb Dray | Chief Operating Officer | USD 403,742 | Female | 1987 | Active |
Eric H. Yecies | Chief Legal Officer, General Counsel & Corporate Secretary | USD 332,000 | Male | 1978 | Active |
Chris Pisano | Chief Marketing Officer | — | Male | 1975 | Active |
Maria E. Stan | Chief Accounting Officer & Controller | — | Female | 1975 | Active |
James Porte | SVP of Care Center Operations | — | Male | — | Active |
LifeMD (NASDAQ: LFMD - Get Free Report) and Ryman Healthcare (OTCMKTS:RYHTY - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares LifeMD and
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on August 5, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2026, to holders of record at the close of business on July 3, 2026.
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Umesh Sripad as Chief Technology Officer (CTO), effective immediately. In this role, Mr. Sripad will lead LifeMD's technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and enterprise scalability initiatives as the company continues its rapid expansion.
